Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination☆

摘要: Abstract Background/Aims After liver transplantation (LT) for HCV-related cirrhosis, recurrence of HCV infection is universal and the risk progression to cirrhosis high. The modalities efficacy antiviral therapy in this indication are still controversial. We present here results a pilot study 12-month combination by pegylated alfa2b-interferon (PEG-IFN) ribavirin 20 patients. Methods Twenty patients entered (13 male 7 female, median age 53.8 years). In 80% patients, was genotype 1. delay between LT 28 months. doses were progressively increased from 0.5 1 μg/kg/week PEG-IFN 400 1000–1200 mg/d ribavirin. Follow-up based on biochemical (ALT), virological (HCV-RNA) histological (liver biopsy) examinations. Results Four (20%) withdrawn due adverse effects. 6 dose had be reduced μg/kg/week. A reduction 13/16 cases onset anemia. Histological evidence mild acute rejection immunosuppressive regimen 5/20 At end treatment, 75% response 55% response. mean METAVIR score, according activity fibrosis, A1.8 F2.2 before treatment A0.3 F1.6 at treatment. 9/20 persisted months after Conclusions Our suggest that may well tolerated beneficial during recurrent hepatitis C transplant recipients.